Our Leadership

Precision Medicine Experts at RPRDx

Our Leadership

At RPRD, our team of experts lead in the implementation and advancement of precision medicine. Their decades of experience developing innovative solutions in medical genetics and their thoughtful consultancy guides clinicians, researchers, and drug developers as they implement and advance precision medicine in their fields.

Ulrich Broeckel, MD

Ulrich Broeckel, MD – Founder & Chief Executive OfficerFounder & Chief Executive Officer

Ulrich Broeckel, MD, is a leading physician-scientist with over 20 years of experience in genetics and genomics and more than 10 years of experience in clinical diagnostics. He is an expert in translational pharmacogenomics research and is a member of the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the NIH initiatives on clinical pharmacogenomics. Dr. Broeckel also serves as Professor of Pediatrics, Section Chief of Genomic Pediatrics, and Associate Director for Pharmacogenomics, Genomic Sciences, and Precision Medicine Center at the Medical College of Wisconsin. Read more about Dr. Broeckel and his research team’s scientific achievements and research interest.

Gunter Scharer, MD, PhD

Chief Medical Officer & Medical Director

Gunter Scharer, MD, is a board-certified medical geneticist with 15+ years of clinical and laboratory experience. He is board certified in Clinical Genetics, Clinical Molecular Genetics, and Medical Biochemical Genetics, and licensed to practice in multiple states. Dr. Scharer is a renowned geneticist with deep experience in rare disorders and mitochondrial disease. He is a member of the Clinical Pharmacogenetics Implementation Consortium (CPIC) and Pharmacogenomics Research Network (PGRN). Prior to joining RPRD, Dr. Scharer was the director of the Department of Medical Genetics and Genomics at Children’s Minnesota and Adjunct Associate Professor in Pediatrics at the Medical College of Wisconsin.

Amy Turner

Director, Operations and Innovation

Amy is a leading scientist with over 10 years of experience in pharmacogenomics and precision medicine translational research. She is responsible for RPRD’s cutting-edge method development and lab operation. Amy is an active participant of the PharmVar Consortium and serves as a Gene Expert Panel member. She leads multiple collaborative projects with academic institutions, healthcare organizations, and drug developers to further all pharmacogenomics applications. Amy’s awareness of technological trends coupled with her extensive insight into the dynamic pharmacogenomics landscape allows her to provide RPRD clients with the most advanced pharmacogenomics consultation available.

Andrea Matter, MS

Director, Regulatory Affairs

Andrea leverages over a decade of experience in clinical diagnostics, specializing in CLIA/CAP compliance, quality management, and GMP documentation. She provides consultation to RPRD clients on all of their compliance needs, ranging from patient privacy (HIPPA) and safety for healthcare management to understanding FDA guidelines. Andrea understands that robust quality standards and continuous improvement are the keys to providing RPRD clients with superior pharmacogenomics results. Testing accuracy and patient safety is always her top priority.

Lina Li, PhD, MBA

Lina Li, PhD, MBA

Director, Marketing & BD

Lina Li brings more than 10 years of experience in marketing, account management and strategic planning in the healthcare industry. She served as market development manager at Life Technologies, a world-leading biotechnology company, where she developed and executed several successful go-to-market strategies for new product launches and oversaw multiple marketing campaigns that drove double-digit annual revenue growth. Prior to joining RPRD, Lina served as a planning strategist for ProHealth Care. She received her PhD from the University of Cardiff, UK, and MBA from the University of Wisconsin.

Praful Aggarwal, MS

Director, Informatics

Praful is a bioinformatics expert in pharmacogenomics data analysis, clinical interpretation and reporting with 9+ years of experience. His in-depth knowledge of data analysis, translation and reporting, using various cutting-edge genetic analysis platforms, enables him to provide complete informatics and consulting services in a wide range of applications, including clinical implementation, scientific research, and drug development. He integrates the latest clinical guidelines into bioinformatics solutions to help clients achieve their goals for knowledge-based pharmacogenomics implementation.

Board of Directors

Ulrich Broeckel, MD – Founder and CEO

Ulrich Broeckel, MD, is a leading physician-scientist with over 20 years of experience in genetics and genomics and more than 10 years of experience in clinical diagnostics. He is an expert in translational pharmacogenomics research and is a member of the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the NIH initiatives on clinical pharmacogenomics.

Carter Cliff – Founder

Carter Cliff is an entrepreneur with 15 years of experience in biotech, recently focused on induced-pluripotent stem cell (iPSC)-based regenerative medicine. He is a founder of Opsis Therapeutics, Dianomi Therapeutics, and Vascugen where he currently serves at CEO. Previously he held various positions at leading platform technology companies including Cellular Dynamics (acquired by FUJIFILM), Meso Scale Diagnostics (privately held), Life Technologies (acquired by Thermo Fisher Scientific), and Ingenuity Systems (acquired by Qiagen).

Susan Slocum, MBA

Susan Slocum has over 30 years experience in investment management with more than 25 years in health care investment management. She currently serves as Treasurer & Investment Officer for Children’s Hospitals and Clinics of Minnesota, one of the 10 largest pediatric systems in the United States. Sue has achieved top 15th percentile returns on an endowment investment portfolio over 5 years ending June 30, 2018 as CIO of the seventh-largest pediatric health care system. She has managed $1.4 billion in invested assets and an additional $1.7 billion in multi-employer union pension plan.

Border Image